Meta-analysis Evaluating the Effect of Sodium-Glucose Co-Transporter-2 Inhibitors on the Risk for New-Onset Obstructive Sleep Apnea in Patients With Type 2 Diabetes Mellitus Regardless of Cardiovascular Disease at Baseline

Obstructive sleep apnea (OSA) is a relatively common, chronic sleep disorder closely related to type 2 diabetes mellitus (T2DM).1 OSA is also related to cardiovascular disease development, representing a modifiable cardiovascular risk factor.2 It is an independent risk factor for coronary artery disease, cerebrovascular disease, and all-cause mortality.3 Therefore, its treatment, and preferably its primary prevention, seems to be of utmost importance. Sodium-glucose co-transporter-2 (SGLT-2) inhibitors, a novel class of antidiabetics, have revolutionized the treatment of patients with T2DM because they exert cardio-protective and reno-protective beneficial effects.